---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Effects of other drugs"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Effects of other drugs. Topics: Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study; Prior FcRn blockers, complement inhibitors, rituximab, immunoglobulin, and plasma exchange: phase 2 exclusions; Prior B-cell therapies, immunoglobulin, and plasma exchange: EMERGE exclusions. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Claseprubart

<a id="topic-2.1.2.9.1-1"></a>

### Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study

> “Part A and Part B have already been registered and this registration of Part C will be evaluating DNTH103 PK following administration of human normal immunoglobulin (Ig)G. Part C will be open label and will not be placebo controlled.”
> “Single dose DNTH103, administered on Day 1 after administration of Privigen NZ solution for IV infusion on Days -8 and -7”
> “IV7, 0.5 g/kg of body weight per day for 2 consecutive days (total dose: 1 g/kg)”
> “Investigational Product: DNTH103 IV infusion, 1 week after Privigen NZ solution: • IV7, 10 mg/kg Investigational Product: DNTH103 SC injection, 1 week after Privigen NZ solution: • IV7, 600 mg”
> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV following administration of IgG, as a single dose in healthy adult volunteers.”
> “Recruitment status Completed”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-2.1.2.9.1-2"></a>

### Prior FcRn blockers, complement inhibitors, rituximab, immunoglobulin, and plasma exchange: phase 2 exclusions

> “Individuals with current or prior use of a complement inhibitor, use of an anti-neonatal Fc receptor agent within 90 days of randomization, use of rituximab within 6 months, or IV immunoglobulin/plasma exchange within 4 weeks of randomization were not permitted to participate in the study.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-2.1.2.9.1-3"></a>

### Prior B-cell therapies, immunoglobulin, and plasma exchange: EMERGE exclusions

> “Rituximab or other B-cell targeting therapies (ie, inebilizumab) within 6 months (180 days) prior to randomization (Day 1); Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1)”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
